Working… Menu

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05035745
Recruitment Status : Recruiting
First Posted : September 5, 2021
Last Update Posted : September 5, 2021
Information provided by (Responsible Party):
National University Hospital, Singapore